Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $800000.0.

  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) fell 1111.11% to $800000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 960.13%. This contributed to the annual value of $3.5 million for FY2024, which is 1813.33% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) stood at $800000.0, which was down 1111.11% from $800000.0 recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF)'s 5-year high stood at $904000.0 during Q1 2024, with a 5-year trough of $224000.0 in Q1 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' median Depreciation & Amortization (CF) value was $700000.0 (recorded in 2023), while the average stood at $612631.6.
  • In the last 5 years, Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) plummeted by 2703.58% in 2022 and then surged by 16785.71% in 2023.
  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) (Quarter) stood at $300000.0 in 2021, then surged by 75.67% to $527000.0 in 2022, then skyrocketed by 62.81% to $858000.0 in 2023, then fell by 4.55% to $819000.0 in 2024, then fell by 2.32% to $800000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $800000.0 in Q3 2025, compared to $800000.0 in Q2 2025 and $801000.0 in Q1 2025.